Skip to main
EOCN

EOCN Earnings Dates & Reports

EOCN Most Recent Earnings

Report Date
Period EndingQ2 2026
Est. EPS-$3.12
Actual EPS-$2.86
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

EOCN Earnings per Share (EPS) History

Signup for full access
Browse free

EOCN Latest Earnings

The value each EOCN share was expected to gain vs. the value each share gained.

EOCN reported its most recent earnings on for Q2 2026, posting earnings per share (EPS) of -$2.86. This exceeded analysts' expectations of -$3.12 by 8.33%, marking a Beat.

For comparison, Galmed Pharmaceuticals Ltd reported EPS of -$5.04 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$3.06.

EOCN Earnings History

Earnings
Est. EPSActual EPSSurprise
Q3 2026
-$3.06
Q2 2026
-$3.12-$2.86-8.33%
Q1 2026
-$3.04-$2.32-23.68%
Q4 2025
-$4.08-$7.36+80.39%
Q3 2025
-$4.32-$2.64-38.89%
View all

EOCN Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Galmed Pharmaceuticals Ltd’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

EOCN Earnings FAQs

EOCN last reported earnings on Sep 2, 2026 for Q2 2026, posting an EPS of -$2.86, which Beat the estimate of -$3.12 by 8.33%.

For Q2 2026, EOCN reported an EPS of -$2.86, exceeding analysts' estimate of -$3.12 by 8.33%.

For Q2 2026, EOCN Beat expectations with an actual EPS of -$2.86 vs. an estimated EPS of -$3.12.

Following the last earnings report on Sep 2, 2026, EOCN's stock price moved — from — to —.

The next EOCN earnings call is scheduled for Nov. 25, 2026, where executives will discuss financial results and outlook.

Galmed Pharmaceuticals Ltd (EOCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.